• NovaBridge Biosciences replaced PwC as independent auditor with Deloitte, effective June 16, 2026, for the fiscal year ending Dec. 31, 2026.
• PwC audit opinions for fiscal 2025 and 2024 were clean, with no adverse opinion, disclaimer, or scope or accounting qualifications.
• No reported auditor disagreements; the only cited reportable issue was material weaknesses in IT general controls at Dec. 31, 2025 and 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001778016-26-000005), on June 16, 2026, and is solely responsible for the information contained therein.